Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0022 • ACR Convergence 2023
Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients
Erika Hubbard¹, Prathyusha Bachali², Kathryn Kingsmore Allison¹, Amrie Grammer¹ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA
Background/Purpose: We previously developed a novel machine learning (ML) pipeline leveraging analysis of gene expression data to identify subsets of SLE patients with common molecular…
Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Jessica Ellis¹, Anita McGrogan², Neil McHugh², Ben Mulhearn³, Eleanor Korendowych⁴, John Pauling⁵, Ian Bruce⁶, Jenny Humphreys⁷ and Sarah Skeoch¹, ¹University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Bath, Bath, United Kingdom, ³Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Manchester, Stockport, United Kingdom
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…
Abstract Number: 0191 • ACR Convergence 2023
Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Meredith Xepoleas¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, with a higher burden in non-Caucasian populations. Due to the increased risk of adverse…
Abstract Number: 0545 • ACR Convergence 2023
Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)
Vineeta Shobha¹, Liza Rajasekhar², Shaleni V¹, Arul Rajamurgan³, VijayKR Rao⁴, Subramanian Nallasivan⁵, Dr Yogesh Preet Singh⁶, Avinash Jain⁷, Aradhana Singh⁸, Franciosalgeo George¹, Sourabh Malviya⁹, Deepak Yadav¹⁰, John Mathew¹¹ and Amita Aggarwal¹⁰, ¹St. John's National Academy of Health Science, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Madras Medical College, Chennai, India, ⁴Divisha Arthritis and Medical Center, Bangalore, India, ⁵Velammal Medical College Hospital, Madurai, India, ⁶Himalayan Institute of Medical Sciences, Dehradun, India, ⁷SMS Medical College, Lucknow, India, ⁸SMSMC&H, Jaipur, India, ⁹Medanta super speciality Hospital, Indore, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹¹Christian Medical College Vellore, Vellore, India
Background/Purpose: Early diagnosis remains an unmet need for SLE patients across the world. Reasons for delay in diagnosis differ in various geographic regions and largely…
Abstract Number: 0562 • ACR Convergence 2023
HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
Ivan Ferraz Amaro¹, Maria García-González¹, Fuensanta Gómez-Bernal¹, Juan Carlos Quevedo-Abeledo², Yolanda Fernández-Cladera¹, Agustín F González-Rivero¹ and Miguel A Gonzalez-Gay³, ¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages, has been linked to cardiovascular events. Systemic lupus…
Abstract Number: 0580 • ACR Convergence 2023
Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus
Gayathri MS, Aishwarya Gopal, Molly Mary Thabah, Christina Mariaselvam, jaiveer Singh and Chengappa Kavadichanda, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality in systemic lupus erythematosus (SLE). Role of conventional risk scores which predict cardiovascular events, to…
Abstract Number: 0597 • ACR Convergence 2023
Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Withrop⁷, Ihor Hupka⁸, Micki Hultquist⁹, Raj Tummala⁹, Gabriel Abreu¹⁰, Catharina Lindholm¹⁰ and Hussein Al-Mossawi¹¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁸BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland, ⁹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹⁰BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a systemic autoimmune disease requiring long-term treatment. In this placebo-controlled phase 3 TULIP long-term extension (LTE) study,1 the impact of anifrolumab in…
Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
May Choi¹, Hongshu Guan², Kazuki Yoshida³, Benjamin Kargere⁴, Jack Ellrodt⁵, Emma Stevens², Tianrun Cai², Brendan Everett², Brittany Weber² and Karen Costenbader⁶, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Takeda, Boston, MA, ⁴Williams College, Boston, MA, ⁵Williams College, Williamstown, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
Abstract Number: 0889 • ACR Convergence 2023
Axl Receptor Tyrosine Kinase Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization
Wenwen Pei¹, Ranran Yao¹, Ziye Wang², Ruyu Liang³, Renge Liang², Xiaolin Sun⁴ and Yin Su², ¹Peking University, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Peking University, XiCheng, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: Diffusealveolar hemorrhage (DAH) is an infrequent but life-threatening complication in patients with systemic lupus erythematosus (SLE). Cells of the monocyte/macrophage lineage are essential to…
Abstract Number: 0909 • ACR Convergence 2023
Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Joy Park¹, Xiaojing Wang², Aparna Godavarthy¹, Akshay Patel², Krakko Daniel¹, Jessica Nolan¹, Joanne Chilton¹, Bryan Blaker¹ and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 0930 • ACR Convergence 2023
Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Aastha Khatiwada¹, bethany wolf², Isabelle Ayoub³, Juan Mejia-Vilet⁴, Ana Malvar⁵, Carl Langefeld⁶, Brad Rovin³, Jim Oates² and Betty Tsao², ¹National Jewish Health, Denver, CO, ²Medical University of South Carolina, Charleston, SC, ³Ohio State University, Columbus, OH, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Hospital Fernandez, Buenos Aires, Argentina, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
Abstract Number: 1224 • ACR Convergence 2023
Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic
Audrea Chen¹, Tala El Tal², Asha Jeyanathan¹, Holly Convery¹, Stephanie Wong¹, Linda Hiraki¹, Deborah Levy¹ and Andrea Knight¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Common barriers to conducting mental health (MH) screening in pediatric clinics include provider uncertainty with follow-up after screening, and concern with increasing burden of…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 1452 • ACR Convergence 2023
Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Audrey Hagiwara, Moumita Bose, Marianne Bernardo, Michael Nelson, Mariko Ishimori, Daniel Berman, C. Noel Bairey Merz, janet wei and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Women with SLE have an elevated risk of cardiovascular disease. Many women with SLE frequently report chest pain in the absence of obstructive coronary…
Abstract Number: 1469 • ACR Convergence 2023
Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Daniel Joyce¹, Jeffrey. Berger², Allison Guttmann³, Ghadeer Hasan⁴, Jill Buyon⁵, H Michael Belmont¹, Jane Salmon⁶, Anca Askanase⁷, Joan Bathon⁸, Laura Geraldino-Pardilla⁹, Yousaf Ali¹⁰, Ellen Ginzler¹¹, Chaim Putterman¹², Caroline Gordon¹³, Charles Helmick¹⁴, Kamil Barbour¹⁵, Heather Gold¹⁶, Hilary Parton¹⁷ and Peter Izmirly², ¹NYU School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Atlantic Health System, Summit, NJ, ⁴Optum, Jersey City, NJ, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Columbia University Medical Center, New York, NY, ⁸Columbia University, New York, NY, ⁹Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, ¹¹SUNY Downstate Health Sciences University, Brooklyn, NY, ¹²Albert Einstein College of Medicine, Bronx, NY, ¹³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁴NA, Atlanta, GA, ¹⁵Centers for Disease Control and Prevention, Atlanta, GA, ¹⁶New York University, New York, NY, ¹⁷New York City Department of Health and Mental Hygiene, Queens, NY
Background/Purpose: Patients with SLE are at increased risk for cardiovascular disease (CVD). Population estimates of CVD in SLE remains limited for non-White racial/ethnic populations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].